| April 19,
2004: TORONTO, CANADA and WORCESTER, MA: VisualSonics
Inc. is pleased to announce that it is sponsoring and presenting
its Vevo 660™ high-resolution in vivo imaging
system for small animal cancer research at the “Small
Animal Imaging for Cancer Research” Workshop at the University
of Massachusetts. The sold-out workshop will be held from April
19 – 21, 2004. “With the growing use of in
vivo imaging for cancer phenotyping of small animals,
we applaud the leadership that the University of Massachusetts
has taken in developing this Workshop and VisualSonics is
pleased to sponsor and present our Vevo 660™ imaging
system,” said Tom Little, CEO of VisualSonics Inc. “We
believe that with the utility of high-resolution ultrasound
to view and quantify orthotopic and subcutaneous tumors in
mice and rats — in vivo — to detect apoptosis,
to visualize vasculature in and around tumors and to monitor
the effectiveness of therapeutics in longitudinal studies,
the rapid adoption of high-resolution ultrasound will continue
within the preclinical marketplace. We fully support U Mass’s
strategy of helping scientists better understand the utility
of in vivo imaging through hands-on demonstrations
of the modalities.” As part of the 3-day Workshop, scientists
will have the opportunity to hear lectures presented from
subject matter experts representing six major imaging modalities
(high-resolution ultrasound, small animal magnetic resonance
imaging, optical, microSPECT/microCT and microPET) for small
animal imaging for cancer research. The 50-some attendees
will then rotate through four 4-hour in vivo demonstrations,
having the ability to observe and participate in imaging sessions
of mice with five of the modalities.
“We are pleased to provide the forum to bring together
leading authorities and scientists along with the preclinical
imaging industry leaders in an intensive and scientifically-focused
workshop”, said Dr. Don Hnatowich, Professor, Radiology,
Division of Nuclear Medicine, Department of Radiology, University
of Massachusetts Medical School. “The fact that the
course is oversubscribed – from delegates traveling
globally as well as across North America – reflects
the growing interest for in vivo imaging as a key component
to small animal research studies of cancer and other diseases.”
About University of Massachusetts Medical School
The University of Massachusetts Medical School, the
State’s only public academic health center, opened its
doors in 1970 and its teaching hospital in 1976 with a stated
mission of serving the people of the Commonwealth through excellence
in health sciences, education, clinical care, research and public
service. The academic
center includes the Medical School, the Graduate School of Biomedical
Sciences, the Graduate School of Nursing and Graduate Medical
Education. The medical center is one of the fastest growing
medical schools in the country and has built a reputation as
a world-class research institute consistently producing advances
in clinical and basic research. The University of Massachusetts
Medical School is ranked among the nation’s top five primary
care training sites, and attracts over $143 million in research
funding annually.
The merger of the University of Massachusetts Medical Center
with Memorial Hospital in April 1998, formed UMass Memorial
Health Care, an integrated system covering the complete health
care continuum with teaching hospitals, affiliated community
hospitals, freestanding primary care practices, ambulatory
outpatient clinics, a long-term care facility, home health
agency, rehabilitation group and mental health services. UMass
Memorial is the clinical partner of the University of Massachusetts
Medical School.
About VisualSonics
VisualSonics Inc. (www.visualsonics.com)
is the leading manufacturer of high-resolution in vivo
imaging systems for small animal research. VisualSonics’ Vevo
660™ high-resolution imaging system provides real-time visualization
and measurement of anatomical and hemodynamic function in small
animals down to 30 microns. Because of the non-invasive nature
of the technology, longitudinal studies of the same animal can
be performed. This high-resolution imaging technology is being
successfully applied to phenotypic-based research applications
such as developmental biology, cardiovascular research, cancer
biology, neurobiology and preclinical drug discovery.
For more information, contact:
VisualSonics Contact:
Tom Little
President and CEO, VisualSonics Inc.
VisualSonics Inc.
Tel. 416.484.5010
Cell. 416.580.5032
Email tlittle@visualsonics.com
Web www.visualsonics.com
University of Massachusetts Contact:
D. J. Hnatowich, Ph.D.
Professor, Radiology, Division of Nuclear Medicine, Department
of Radiology
University of Massachusetts Medical School
Tel: (508) 856-4256
Fax: (508) 856-4572
Email: donald.hnatowich@umassmed.edu
|
|